Estriol is a local vaginal oestrogen cream for adult women experiencing menopausal vaginal symptoms. It helps restore moisture, thickness and elasticity in vaginal tissues by acting mainly at the treatment site.
Estriol is a local oestrogen cream containing estriol 0.01% w/w, supplied in an 80 g tube with an applicator. Estriol is an oestrogen hormone used in local vaginal therapy for genitourinary symptoms of menopause.
Estriol contains estriol 0.01% w/w. Estriol is an oestrogen hormone used in local vaginal therapy for genitourinary symptoms of menopause.
Menopause can lower vaginal oestrogen levels. The vaginal lining may then become thinner, less elastic and more prone to micro-irritation. This process is often called vaginal atrophy or genitourinary syndrome of menopause.
Estriol cream is intended for intravaginal use with the supplied applicator. The medication acts mainly at the treatment site, which distinguishes it from systemic hormone therapy taken as tablets, patches or gels.
The UK Summary of Product Characteristics for estriol vaginal cream describes local treatment for postmenopausal vaginal symptoms caused by oestrogen deficiency [1]. The dose is stated on the pack — follow the leaflet.
Estriol cream is applied into the vagina using the applicator supplied with the tube. The prescribed amount and treatment schedule should be followed exactly, since local oestrogen plans often include an initial regular-use phase followed by a lower-frequency maintenance phase.
If a scheduled application is missed, use it when remembered unless the next planned dose is near. Do not apply a double amount to compensate for a missed application.
Improvement may start within several weeks, though tissues affected by long-standing oestrogen deficiency often need continued treatment to maintain comfort. NICE guidance recognises vaginal oestrogen as a treatment option for genitourinary symptoms associated with menopause [3].
Estriol binds to oestrogen receptors in vaginal cells. These receptors regulate cell renewal, blood flow, tissue thickness and natural lubrication.
With regular local treatment, the vaginal lining can become less fragile. Vaginal pH may also move towards a more acidic range, which supports the normal vaginal environment. Relief is usually gradual rather than immediate.
Estriol is a weaker oestrogen than estradiol. Its local vaginal use is designed to target symptoms such as dryness and soreness with much lower systemic exposure than full-body hormone therapy.
A reduction in dryness is often the first change noticed.
Burning and discomfort may take longer to settle.
The European Medicines Agency has evaluated estriol-containing medicines and stresses that dose strength, duration and route of use affect systemic exposure to oestrogen [2].
It is used by adult women with vaginal symptoms linked to reduced oestrogen after menopause, including dryness, burning, irritation and discomfort during intercourse. Applied inside the vagina, estriol helps restore the thickness, elasticity and moisture of vaginal tissues.
| Approach | Main action | Best suited to |
|---|---|---|
| Estriol vaginal cream | Local oestrogen effect on vaginal tissue | Dryness, irritation, pain during intercourse and vaginal atrophy |
| Non-hormonal vaginal moisturiser | Adds temporary moisture and reduces friction | Mild dryness or occasional discomfort |
| Systemic menopausal hormone therapy | Raises oestrogen levels throughout the body | Vaginal symptoms combined with troublesome hot flushes or night sweats |
A moisturiser can reduce friction, yet it does not reverse oestrogen-related thinning of the vaginal lining. Estriol cream is more targeted when dryness, soreness and recurrent irritation are linked to menopause.
Systemic hormone therapy may be considered when whole-body menopausal symptoms are present. It has a different risk profile because hormones circulate more widely in the body. Local estriol is generally chosen when symptoms are mainly vaginal or urinary.
Estriol is not for you if you have unexplained vaginal bleeding, known or suspected oestrogen-dependent cancer, a previous blood clot linked to oestrogen treatment, active liver disease, or an allergy to estriol or another cream component.
Use also requires careful prescriber assessment if you have:
Estriol can be affected by medicines that alter liver enzyme activity, including certain epilepsy medicines, rifampicin, rifabutin and some antiretroviral treatments. St John’s wort may also reduce oestrogen exposure. Tell the prescriber about all regular medicines, vaginal products and herbal remedies.
Unexpected bleeding after menopause should be assessed before starting oestrogen therapy. New bleeding after treatment has been established also needs prompt medical review.
Talk to a prescriber before using Estriol if you have had breast, womb or ovarian cancer, blood clots, a stroke or heart attack, or if you have liver, kidney, heart, blood pressure, migraine, epilepsy, gallbladder, clotting or autoimmune problems. Make sure they know about every medicine, vaginal product and herbal remedy you use.
Most women tolerate local estriol cream well. Mild local effects can occur during the first days of use, when vaginal tissue is already dry or irritated.
Possible effects include:
Brief stinging after application can happen when the vaginal lining has tiny cracks from dryness. Persistent burning, worsening pain or a new rash needs medical assessment.
Stop using Estriol and seek urgent medical care for swelling of the face or throat, sudden chest pain, breathlessness, one-sided leg swelling, yellowing of the skin, severe new migraine-like headache, or unexpected heavy vaginal bleeding.
The North American Menopause Society reported in 2022 that low-dose vaginal oestrogen is an established option for bothersome genitourinary syndrome of menopause, with treatment selected according to symptoms and individual medical history [4].
A second common mistake is expecting Estriol to treat every menopausal symptom. Local vaginal estriol is directed at vaginal and urinary symptoms; it is not designed as primary treatment for severe hot flushes, sleep disturbance or mood symptoms.
In clinical practice, doctors often see vaginal symptoms dismissed as an unavoidable part of ageing. They are common, treatable and can affect sleep, sexual comfort, exercise and urinary comfort.
Doctors usually explain that Estriol is not a fast-acting lubricant. It works by improving hormone-responsive vaginal tissue over time. Consistency matters during the initial treatment phase, while maintenance treatment is often needed because symptoms can return after therapy stops.
A clinician will also ask about postmenopausal bleeding, previous cancer, clotting history and use of systemic hormone therapy. These questions are not routine paperwork; they determine whether local oestrogen is suitable and how it should be monitored.
The American Urological Association, Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction and American Urogynecologic Society included local low-dose vaginal oestrogen among treatment options for genitourinary syndrome of menopause in their 2025 guideline [5].
Some women notice less dryness or burning within a few weeks, while fuller improvement can take longer because vaginal tissue needs time to recover. Consistent use during the prescribed starting phase supports the local effect. NICE guidance supports reviewing symptom response during follow-up. NICE guidance updated in 2024 lists vaginal oestrogen among treatments for menopausal genitourinary symptoms. The speed of response varies with symptom severity and treatment consistency.
Estriol may reduce pain linked to menopausal vaginal dryness, thinning and reduced elasticity. It does not create sexual desire directly, but improved tissue comfort can make intercourse less painful. The North American Menopause Society’s 2022 position statement includes low-dose vaginal oestrogen among therapies for genitourinary syndrome of menopause. Pain that remains severe or is accompanied by bleeding needs medical assessment.
Estriol cream is local vaginal oestrogen therapy, while systemic hormone therapy is designed to deliver hormones throughout the body. Local treatment is often selected when vaginal dryness, irritation or urinary discomfort are the main concerns. The EMA’s 2020 assessment of estriol-containing medicines explains why concentration, route and duration matter when considering oestrogen exposure. A history of hormone-sensitive cancer or blood clots still needs prescriber review.
A simple, fragrance-free lubricant may be used for additional comfort during intercourse if needed. Do not apply another vaginal product at the same time as Estriol unless the timing has been agreed with the prescriber, since products may mix or increase irritation. The 2025 AUA guideline discusses moisturisers, lubricants and local hormone treatment as separate approaches for genitourinary syndrome of menopause. Water-based, unperfumed products are often better tolerated by sensitive tissue.
Reduced vaginal oestrogen can contribute to urinary urgency, burning and repeated urinary symptoms in some postmenopausal women. By improving vaginal and urethral tissue health, local oestrogen may support urinary comfort for selected patients. The AUA, SUFU and AUGS guideline published in 2025 addresses local low-dose vaginal oestrogen within care for genitourinary syndrome of menopause. Fever, flank pain or visible blood in urine requires urgent medical evaluation rather than self-treatment.
Mild, short-lived stinging can occur when dry tissue first comes into contact with cream. Persistent burning, swelling, rash, worsening itch or pain suggests irritation or sensitivity and should be assessed before further use. The electronic Medicines Compendium's 2024 Summary of Product Characteristics for estriol vaginal cream lists local irritation among possible adverse effects. Avoid fragranced soaps and intimate sprays while symptoms settle.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.
I used it at night as prescribed. The first few applications felt slightly warm, but that settled after several days. By the fourth week, intercourse was much more comfortable and I was not waking up with that dry, irritated feeling.
The applicator took a little practice. I found lying down before bed much easier than trying to apply it in the morning. The dryness improved slowly rather than overnight, which was frustrating at first, but I noticed a real change after regular use.
It helped the itching, though I had mild discharge at the beginning and used a liner for a few nights. I also stopped using scented wash products, and that made a bigger difference than I expected.
I had spotting after starting, so I stopped and contacted my doctor. It was not something I wanted to ignore. The irritation improved, but the bleeding needed checking before I continued.
